IAP5 Rec'd PCT/PTO 10 FEB 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. TBD; MBHB05-1038-C5) 10/567765

In the Application of:)
Kaydk et al.))
Serial No.: TBD) Examiner: TBD
) Group Art Unit: TBD
Filing Date: TBD)
For: MELKS as Modifiers of the RAC Pathway And Methods of Use))

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. All references cited are also listed in the PTO/SB/08B form enclosed herewith.

The Office has amended the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications. See 69 Fed. Reg. 56481. In accordance with this amendment, cited U.S. patents and U.S. patent application publications are not enclosed.

As this Information Disclosure Statement is being submitted after receipt of a foreign search report, a copy of the search report is attached herewith.

This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

IAP5 Rec'd PCT/PTO 10 FEB 2006 10/567765

Applicants do not believe any fee is due with this submission. If this belief is in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Date: <u>LeV 10</u> 2006

By:

Anita J. Terpstra

Reg. No. 47,132

McDonnell Boehnen Hulbert & Berghoff LLP 300 South Wacker Drive, 32nd Floor

Chicago, IL 60606

Telephone: 312-913-0001 Facsimile: 312-913-0002

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO					Complete if Known				
					Application No.	10/5670765			
	INF	ORMATION DISC	LOS	SURE	Filing Date:	TBD			
STATEMENT BY APPLICANT (Use as many sheets as necessary)					First Named Inventor Lisa Kaydk				
					Art Unit	, TBD			
(300 do many onodo do nododaly)					Examiner Name	unassigned			
Sheet			of	1	Attorney Docket Number	05-1038-C5			
						12 miles			
		:	<u>`</u> _	U.S. PATENT DO	OCUMENTS	e de la companya della companya dell			
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant			
		Number-Kind Code ^{2 (if kno}	own)			Figures Appear (60)			
	Α	US-2003/0198972		10/23/03	Erlander et al.				
						A Mar II			
						-			
	- 35		NON	PATENT LITERAT	TURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published							
	1.	Heyer et al., "Expression of <i>Melk</i> , a New Protein Kinase, During Early Mouse Development," <i>Developmental Dynamics</i> , 215:344-351 (1999)							
	2.	Heyer et al., "New Member of the Snf1/AMPK Kinase Family, <i>Melk</i> , Is Expressed in the Mouse Egg and Preimplantation Embryo," <i>Molecular Reproduction and Development</i> , 47:148-156 (1997)							
	3.	International Search Report for PCT/US04/26231 mailed May 23, 2005							

Examiner			Date	-717
Signature	 		Considered	1.77

Vulsteke et al., "Inhibition of Spliceosome Assembly by the Cell Cycle-regulated Protein Kinase MELK and Involvement of Splicing Factor NIPP1*," The Journal of Biological Chemistry, 279(10):8642-8647 (2004)

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.